DE60321466D1 - Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase - Google Patents

Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase

Info

Publication number
DE60321466D1
DE60321466D1 DE60321466T DE60321466T DE60321466D1 DE 60321466 D1 DE60321466 D1 DE 60321466D1 DE 60321466 T DE60321466 T DE 60321466T DE 60321466 T DE60321466 T DE 60321466T DE 60321466 D1 DE60321466 D1 DE 60321466D1
Authority
DE
Germany
Prior art keywords
drug
hiv
phenotypic
reverse transcriptase
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60321466T
Other languages
English (en)
Inventor
Hilde Azijn
Bethune Marie-Pierre T M M De
Johan Hendrika Vingerhoets
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen R&D Ireland ULC
Original Assignee
Tibotec Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharmaceuticals Ltd filed Critical Tibotec Pharmaceuticals Ltd
Application granted granted Critical
Publication of DE60321466D1 publication Critical patent/DE60321466D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
DE60321466T 2002-07-01 2003-06-30 Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase Expired - Lifetime DE60321466D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39300502P 2002-07-01 2002-07-01
PCT/EP2003/050280 WO2004003223A2 (en) 2002-07-01 2003-06-30 New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance

Publications (1)

Publication Number Publication Date
DE60321466D1 true DE60321466D1 (de) 2008-07-17

Family

ID=30000959

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60321466T Expired - Lifetime DE60321466D1 (de) 2002-07-01 2003-06-30 Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase

Country Status (7)

Country Link
US (2) US7473524B2 (de)
EP (1) EP1522039B1 (de)
AT (1) ATE397669T1 (de)
AU (1) AU2003251732B2 (de)
CA (1) CA2490764C (de)
DE (1) DE60321466D1 (de)
WO (1) WO2004003223A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0011555A (pt) * 1999-05-28 2002-02-26 Virco Nv Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
WO2002033638A2 (en) * 2000-10-20 2002-04-25 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
WO2004003817A1 (en) * 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
US7473524B2 (en) * 2002-07-01 2009-01-06 Hilde Azijn Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
US20050214744A1 (en) * 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
EP2142650B1 (de) * 2007-04-10 2013-05-22 Emory University Neue hiv-1-reverse-transkriptase-codon-deletion und verwendung davon bei der handhabung und behandlung von hiv-infektionen

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US327742A (en) 1885-10-06 Machine for making nuts
DE3235565A1 (de) 1982-09-25 1984-03-29 Boehringer Ingelheim KG, 6507 Ingelheim Piperidinderivate, ihre herstellung und verwendung
JPS5974341A (ja) 1982-10-19 1984-04-26 Nissan Motor Co Ltd 車両用アクセル制御装置
GB2229340B (en) 1989-03-17 1994-02-09 Technophone Ltd Radio telephone system
GB8918226D0 (en) 1989-08-09 1989-09-20 Wellcome Found Dna assays
EP0428000A1 (de) 1989-11-03 1991-05-22 Abbott Laboratories Fluorogene Substrate zum Nachweis von proteolytischer Enzymaktivität
US5235039A (en) 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
WO1993023574A1 (en) * 1992-05-14 1993-11-25 Kozal Michael J Polymerase chain reaction assays for monitoring antiviral therapy
US6063562A (en) 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
ATE217971T1 (de) * 1996-01-26 2002-06-15 Virco Nv Verfahren zur überwachung der chemotherapie von hiv-positiven patienten basierend auf der phenotypischen medikamentempfindlichkeit vom hiv stamm des patienten
JPH11502727A (ja) 1996-01-26 1999-03-09 イノジェネティックス・ナムローゼ・フェンノートシャップ 逆転写酵素遺伝子における薬剤により誘発された変異の検出方法
AP9801360A0 (en) 1996-01-29 1998-12-31 Virologic Incorporated Compositions and methods ofr determining anti-viral drug susceptibility and resistance and anti-viral drug screening.
JP3062459B2 (ja) 1996-08-14 2000-07-10 理化学研究所 ポリエステル重合酵素遺伝子及びポリエステルの製造方法
MXPA00011623A (es) 1998-05-26 2002-10-17 Virologic Inc Medios y metodos para verificar la terapia antirretroviral con inhibidor no nucleosidico de la transcriptasa inversa.
WO1999061666A1 (en) 1998-05-28 1999-12-02 Visible Genetics Inc. Use of polymorphisms as a predictor of drug-resistance mutations
PT2336134T (pt) 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
MXPA00012843A (es) 1998-06-24 2002-04-24 Virologic Inc Medios y metodo para verificar la terapia antirretroviral con un inhibidor nucleosico de la transcriptasa inversa y guia de decisiones terapeuticas en el tratamiento del vih/sida.
AU762811B2 (en) 1998-06-24 2003-07-03 Innogenetics N.V. Method for detection of drug-selected mutations in the HIV protease gene
BR0011555A (pt) * 1999-05-28 2002-02-26 Virco Nv Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
WO2000078996A1 (en) * 1999-06-22 2000-12-28 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
WO2000078994A1 (en) 1999-06-23 2000-12-28 The Penn State Research Foundation Compositions and methods for the quantification of sterol biosynthetic flux
WO2001079540A2 (en) * 2000-04-18 2001-10-25 Virco Bvba Methods for measuring drug resistance
CA2406830C (en) 2000-04-20 2012-10-02 Virco Bvba Method for mutation detection in hiv using pol sequencing
US7058616B1 (en) * 2000-06-08 2006-06-06 Virco Bvba Method and system for predicting resistance of a disease to a therapeutic agent using a neural network
CA2415832C (en) * 2000-06-08 2012-07-24 Brendan Larder Method and system for predicting therapeutic agent resistance and for defining the genetic basis of drug resistance using neural networks
CA2422815A1 (en) 2000-09-15 2002-03-21 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
AU1234402A (en) 2000-10-20 2002-04-29 Virco Nv Establishment of biological cut-off values for predicting resistance to therapy
WO2002033638A2 (en) * 2000-10-20 2002-04-25 Virco Bvba Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
JP2002199890A (ja) 2000-10-23 2002-07-16 Inst Of Physical & Chemical Res 生分解性ポリエステル合成酵素の改変方法
EP1364071A2 (de) 2000-11-10 2003-11-26 Bioalliance Pharma (S.A.) Neue methode zur analyse von phänotypischen eigenschaften des humanen immunschwächevirus (hiv)
ES2275866T3 (es) 2001-02-14 2007-06-16 Tibotec Pharmaceuticals Ltd. 2-(aminosustituido)-benzotiazol-sulfonamidas de amplio esprecto inhibidoras de la proteasa de vih.
EP1319738A1 (de) * 2001-12-17 2003-06-18 Atofina Research S.A. Modifizierte Polyolefinfasern
US7473524B2 (en) * 2002-07-01 2009-01-06 Hilde Azijn Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
WO2004003817A1 (en) * 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
US7294642B2 (en) 2002-09-06 2007-11-13 Elan Pharmaceuticals, Inc. 1,3-Diamino-2-hydroxypropane pro-drug derivatives
EP1605064A1 (de) 2004-06-07 2005-12-14 UMC Utrecht Holding B.V. HIV Varianten, welche einen neuen Resistenzmechanismus gegenüber Proteaseinhibitoren zeigen, diagnostische Assays zum Nachweis der Varianten, und Methoden zur Identifikation von Medikamenten, welche gegen die resistenten Varianten wirksam sind.

Also Published As

Publication number Publication date
WO2004003223A2 (en) 2004-01-08
US7473524B2 (en) 2009-01-06
US20090061420A1 (en) 2009-03-05
AU2003251732B2 (en) 2008-09-18
WO2004003223A3 (en) 2005-02-17
ATE397669T1 (de) 2008-06-15
EP1522039B1 (de) 2008-06-04
CA2490764C (en) 2011-11-22
CA2490764A1 (en) 2004-01-08
US20050239053A1 (en) 2005-10-27
EP1522039A2 (de) 2005-04-13
US8076062B2 (en) 2011-12-13
AU2003251732A1 (en) 2004-01-19

Similar Documents

Publication Publication Date Title
BR0011555A (pt) Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
Metsky et al. Capturing sequence diversity in metagenomes with comprehensive and scalable probe design
Trauner et al. The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy
Lythgoe et al. Shared SARS-CoV-2 diversity suggests localised transmission of minority variants
Liegler et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial
Wu et al. Extrachromosomal DNA: an emerging hallmark in human cancer
Chabria et al. Deep sequencing of HIV: clinical and research applications
DE60327768D1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
Jabara et al. Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection
Van Egeren et al. Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein
DE60321466D1 (de) Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
Dennis et al. Using primer-ID deep sequencing to detect recent human immunodeficiency virus type 1 infection
Fountain-Jones et al. Antiviral treatments lead to the rapid accrual of hundreds of SARS-CoV-2 mutations in immunocompromised patients
Popa et al. Mutational dynamics and transmission properties of SARS-CoV-2 superspreading events in Austria
MXPA03003476A (es) Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco.
ATE375400T1 (de) Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
Kostaki et al. Validation of molecular clock inferred HIV infection ages: Evidence for accurate estimation of infection dates
Ghafari et al. High number of SARS-CoV-2 persistent infections uncovered through genetic analysis of samples from a large community-based surveillance study
WO2002099387A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
Lasek-Nesselquist et al. A statewide analysis of SARS-CoV-2 transmission in New York
Mertz CRISPR Tech Behind Super-Sensitive, Smartphone COVID Test
Williams et al. Research Methods: Translational Research in Geriatric Oncology
Guessous et al. Trends in pharmacogenomic epidemiology: 2001–2007
BR0111575A (pt) Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aids
Minteer et al. A DNAmCULTURE Epigenetic Fingerprint Recapitulates Physiological Aging

Legal Events

Date Code Title Description
8364 No opposition during term of opposition